drugset / Trial / NCT04219124
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
Phase 4
Completed
9 enrolled
University of Leicester
AstraZeneca · collabRoyal Surrey County Hospital NHS Foundation Trust · collab
RandomizedCrossoverDouble-blindOther
Summary
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days. the study aims to investigate the effect of dapagliflozin, a SGLT2 inhibitor, on glucose flux, lipolysis and exercise in patients with type 2 diabetes.
Timeline
- Start
- 2018-09-20
- Primary completion
- 2020-01-08
- Completion
- 2020-01-08
Publications
- Herring RA, Parsons I, Shojaee-Moradie F, Stevenage M, Jackson N, Manders R, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise. J Clin Endocrinol Metab. 2023 Mar 10;108(4):888-896. doi: 10.1210/clinem/dgac617.
- Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, Jackson N, Mendis J, Middleton B, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes. Diabetes Care. 2022 Jun 2;45(6):1408-1415. doi: 10.2337/dc21-2043.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |